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SUMMARY
The importance of innate immunity in cancer is increasingly being recognizedwith
recent reports suggesting tumor cell-intrinsic intracellular functions for innate im-
munity proteins. However, such functions are often poorly understood, and it is
unclear whether these are affected by patient-specific mutations. Here, we
show that C4b-binding protein alpha chain (C4BPA), typically thought to reside
in the extracellular space, is expressed intracellularly in cancer cells, where it in-
teracts with the NF-kB family member RelA and regulates apoptosis. Interest-
ingly, intracellular C4BPA expression is regulated in a stress- and mutation-
dependent manner and C4BPA mutations are associated with improved cancer
survival outcome. Using cell lines harboring patient-specific C4BPA mutations,
we show that increasing intracellular C4BPA levels correlate with sensitivity to
oxaliplatin-induced apoptosis in vitro and in vivo. Mechanistically, sensitive
C4BPA mutants display increased IkBa expression and increased inhibitory Ik
Ba-RelA complex stability. These data suggest a non-canonical intracellular role
for C4BPA in regulating NF-kB-dependent apoptosis.
INTRODUCTION
The importance of innate immunity in cancer is increasingly being recognized, with innate immune path-
ways involved in inflammation, cytosolic nucleic acid sensing, and adaptive immune activation (Hoesel
and Schmid, 2013; MacKenzie et al., 2017). NF-kB family members often regulate downstream effector
functions (such as inflammation and apoptosis) of innate immunity players (Dunphy et al., 2018; Legrand
et al., 2019). NF-kB-dependent transactivation occurs through either the canonical or non-canonical path-
ways (Karin and Lin, 2002; Hoesel and Schmid, 2013). The canonical NF-kB pathway refers to heterodimers
of RelA, c-Rel, and p50, which under unstimulated conditions are retained in the cytoplasm through inter-
action with inhibitors such as the IkB proteins (IkBa, IkBb, IkBe or p105 and IkBg) (Karin and Lin, 2002). In
response to stimuli such as cytotoxic therapy, activation of the IkB kinase (IKK) complex (including IKKa,
IKKb, and IKKg) leads to IKK-dependent phosphorylation of IkBa, targeting it for proteasomal degradation.
IkBa degradation allows translocation of NF-kB dimers (the most abundant being p50-RelA) to the nucleus
and activation of NF-kB target genes including anti-apoptotic targets (Barkett and Gilmore, 1999; Chen
et al., 2000; Karin and Lin, 2002).
In the non-canonical pathway, activation of NF-kB occurs following binding of ‘non-canonical pathway li-
gands’ such as CD40L. Ligand binding allows phosphorylation of IKKa by NF-kB-inducing kinase (NIK).
IKKa phosphorylates precursor protein p100 (IkBd) triggering ubiquitination and partial proteasomal
degradation to p52. p52 can then form a DNA-binding heterodimer with RelB, which translocates to the
nucleus to induce a transcriptional program. NF-kB inhibition in cancer cells reduces NF-kB-dependent
activation of anti-apoptotic genes and is well known to increase sensitivity of cell lines to cytotoxic chemo-
therapy and radiotherapy (Barkett and Gilmore, 1999; Chen et al., 2000; Karin and Lin, 2002).
A comprehensive understanding of how cooperation between innate immunity pathways is modulated in
response to cytotoxic therapies will yield important insights relevant for our understanding of how to improve
cancer therapies. Importantly, we recently reported that somatic mutations in a key innate immunity pathway,
the complement system, are widespread across cancer types and correlate with overall survival outcome, sug-
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is composed of over 40 family members, most of which are thought to be soluble or cell surface proteins having
innate immune functions (Sayegh et al., 2014; Ricklin et al., 2016; Reis et al., 2017). As a first line-of-defense sys-
tem, complement is well poised to exert innate immune effector functions and coordinate with defense path-
ways in order to mount an appropriate response to invading or foreign species (Ricklin et al., 2016). Although
complement is increasingly recognized as a contributor to tumor progression and treatment responses, many
aspects of its role in cancer remain to be explored (Reis et al., 2017). The presence of widespread mutations
in cancer cells suggests that complement-related genes might exert effects inside tumor cells that may be
distinct from their canonical functions. A deeper insight into such intracellular functions, and how theymay regu-
late the interplay with other innate immunity pathways, will be important to further our understanding of tumor
progression and treatment response. Here, we show that C4b-binding protein alpha chain (C4BPA), usually
uniquely thought to form part of extracellular complement regulator C4b-binding protein (C4BP), is expressed
intracellularly in colorectal cancer cells. Furthermore, we report that, intracellularly, C4BPA interacts with NF-kB
pathway member RelA and that increased C4BPA levels regulate NF-kB-mediated anti-apoptotic responses
following oxaliplatin treatment.
RESULTS
C4BPA Interacts with RelA
In an attempt to identify previously uncharacterized functions for negative complement regulators, we searched
the STRINGdatabase for their predicted functional partners (string-db.org).We noted that C4BPA, forming part
of complement regulator C4BP, had non-complement associated predicted partners. Specifically, three mem-
bers of theNF-kB pathway (RelA, NF-kB1 andNF-kB inhibitor, IkBa), were predicted to be present in close inter-
action nodes with C4BPA (Figure 1A). Intrigued by this prediction, we performed immunoprecipitation (IP) ex-
periments to validate the interaction between C4BPA and NF-kB family members. Since we had previously
shown that negative complement regulators are expressed in colorectal cancer cell lines, we chose to perform
IP experiments in HCT 116 colorectal cancer cells (Olcina et al., 2018).
Figure 1. Intracellular C4BPA Interacts with RelA
(A) String.org protein-protein interaction network for C4BPA. Light blue line = known interaction from curated database,
pink line = known interaction experimentally tested, dark green line = predicted interaction, gene neighborhood, light
green line = text mining interaction source, black line = co-expression interaction source, light purple line = protein
homology interaction source.
(B) HCT 116 C4BPAWT cells were transfected with either wild-type (WT) C4BPA or pcDNA3.1. Pull-down with RelA
antibody was performed, and input and immunoprecipitation (IP) for the pull-down is shown. Input was collected from the
same experiment as the pull-down shown. Western blotting was carried out with the antibodies indicated. n = 2. IgG
control is shown in the left lane of the blot.
(C) RKO (colorectal cancer cells with endogenous C4BPA mutation) and HCT 116 (colorectal cancer cells without C4BPA
mutation) were treated with DMSO, oxaliplatin (40 mM, 24 h), or 5-FU (0.1 mg/mL, 24 h). Western blotting was carried out
with the antibodies indicated. b-Actin was used as the loading control. n = 3.
(D) Cellular fractionation followed by western blotting was carried out in HCT 116 C4BPAWT treated with oxaliplatin
(40 mM, 24 h). Tubulin was used as a control for the cytoplasm fraction, and LaminA/C was used as a nuclear fraction
control. Lysate from cells transfected with WT C4BPA was loaded on the right hand side of the gel as a positive control for
the detection of intracellular C4BPA, n = 2.
(E) HCT 116 cells where C4BPA had been depleted by CRISPR/Cas9 technology were transfected with a C4BPA WT
construct (labeled WT OE). The parental line is also shown for comparison (labeled control). Cells were treated with
oxaliplatin (40 mM, 24 h). The graph represents the number of apoptotic/non-apoptotic cells expressed as a % of the
whole population. Individual dots represent values for each independent experiment. Statistical significance was
evaluated by unpaired t test, * = p < 0.05.
(F) KM curve for overall survival of patients with mutations inC4BPA vs patients without mutation across pan-cancer TCGA
data sets (p = 0.0241).
(G) GSEA plot for KEGG pathway ‘Apoptosis’ which appears significantly enriched in patients with mutations in C4BPA
compared to no mutation in this gene in COADREAD patients when RNA-seq data are compared. p value = 0.001605, q
value = 0.0598. NES = 2.48927.
(H) Table showing top enriched pathways in COADREAD patients with C4BPA mutations (compared to patients without
C4BPAmutations) when proteins shown to be differentially expressed in RPPA data are compared and analyzed through
DAVID bioinformatics resource.
(I) HCT 116 cells where C4BPA had been depleted by CRISPR-Cas9 technology were transfected with C4BPA-mutant
constructs, each representing amutation found in colorectal cancer TCGA patients orWTC4BPA. The parental line is also
shown for comparison (labeled con). Cells were treated with oxaliplatin (40 mM, 24 h) and stained for C4BPA.
Representative images are shown. C4BPA = red. DAPI = blue. Scale bar (shown as white bar) = 10.9 mm.
See also Figure S1.
ll
OPEN ACCESS
iScience 23, 101594, October 23, 2020 3
iScience
Article
IP experiments demonstrated that intracellular C4BPA interacts with NF-kB pathway member RelA (Fig-
ure 1B). The intracellular nature of this interaction suggests that the biological consequence might be
related to stress-responsive rather than immune-dependent functions of RelA. Within the context of cancer
treatments, NF-kB-inducing stresses encountered by colorectal cancers include DNA-damaging chemo-
therapeutic agents (Barkett and Gilmore, 1999). We therefore decided to investigate endogenous intracel-
lular C4BPA expression in two commonly used colorectal cancer cell lines (HCT 116 and RKO) treated with
two standard-of-care chemotherapy agents: oxaliplatin and 5-fluorouracil (5-FU) (Pires et al., 2010). We
found that both HCT 116 and RKO cells expressed endogenous C4BPA. Interestingly, in response to oxa-
liplatin, C4BPA protein levels were increased only in RKO cells. No major changes in protein expression
were observed following 5-FU treatment (Figure 1C). In order to gain a better understanding of C4BPA’s
intracellular localization, we performed immunofluorescence experiments and found that C4BPA was
distributed in the cytoplasm where C4BPA staining was found in the same areas as marked by tubulin (Fig-
ure S1A). Furthermore, for themost part, C4BPA did not colocalize with ER chaperone GRP78/BiP, suggest-
ing that perinuclear C4BPA staining does not purely reflect production of the protein in the ER (Figure S1A).
By performing subcellular fractionation experiments, we confirmed that intracellular C4BPA expression is
primarily cytoplasmic in these cell lines and that oxaliplatin does not affect its subcellular localization (Fig-
ure 1D). Together these results indicate that intracellular C4BPA is mostly present in the cytoplasm. These
data are consistent with our finding that C4BPA interacts with RelA even under unstressed conditions in
which RelA would be mostly expected to be present in the cytoplasm (Karin and Lin, 2002). To our knowl-
edge, this is the first report of intracellular C4BPA expression in cancer cells and of stress-dependent
changes in C4BPA expression.
In RKO cells, which displayed oxaliplatin-induced C4BPA expression, we observed a decreased surviving
fraction (compared to HCT 116 cells) particularly in response to oxaliplatin (Figure S1B). We also observed
increased expression of the DNADamage Response (DDR) marker, gH2AX and two pro-apoptotic markers,
cleaved caspase 3 and Bax, as well as increased % apoptosis in RKO in response to oxaliplatin (Figure S1C
and S1D). These data suggest that cells displaying elevated C4BPA expression become more susceptible
to oxaliplatin-induced apoptosis. In order to validate this observation, we overexpressed C4BPA in HCT
116 cells. In line with our hypothesis, C4BPA overexpression resulted in increased apoptosis following ox-
aliplatin treatment (Figures 1E and S1E).
Intrigued by the differences in intracellular C4BPA expression and apoptosis sensitivity found between RKO and
HCT 116 cells, we queried theC4BPAmutational status of these cells and noted that RKO colorectal cancer cells
have a C4BPA missense mutation (c.1384G > A) while HCT 116 cells harbor wild-type (WT) C4BPA. In order to
assess whether genetic alterations of C4BPA occur in patients’ tumors, we queried The Cancer Genome Atlas
(TCGA) data sets and found thatC4BPAmutations and copy number alterations were present in a range of can-
cer types (when pan-cancer studies were queried) (Figure S1F). Interestingly, we found that there was a signifi-
cant association ofC4BPAmutation status and improved outcome whenC4BPAmutations again were analyzed
at the pan-cancer level (and corrected for type, age, and gender) (Figure 1F). We also noted that colorectal can-
cer was one example of several positive cancer types in whichC4BPAmutations appeared to be associated with
improved survival and this association remained even when corrected for age (Figures S1G and S1H and Table
S1). In addition, C4BPA expression in tumors appeared significantly higher than in normal colon tissue (Fig-
ure S1I). The association with survival benefit in colorectal cancers harboring C4BPA mutations, however, did
not correlate with immune response changes such as cytotoxic lymphocyte infiltration or increased cytolytic ac-
tivity (recently found to be associated with improved survival) (Domingo et al., 2016). We found no significant
changes in lymphocyte infiltration or cytolytic activity, suggesting that the association with improved survival
is likely independent of these parameters (Figures S1J and S1K).
Consistent with the previously observed changes in apoptosis, when analyzing patient data by Gene Set Enrich-
ment Analysis (GSEA) of TCGA RNA-seq data, we found that ‘apoptosis’ was the top differentially expressed
pathway in colorectal cancer patients withC4BPAmutations (Figure 1G). Furthermore, analysis of proteins differ-
entially expressed in C4BPA-mutant tumors (from TCGA reverse-phase protein array [RPPA] analysis data) fol-
lowed by Gene Ontology analysis revealed that versions of ‘regulation of apoptosis/cell death’ also ranked as
the top 3 enriched pathways (Figure 1H and Table S2) (Huang et al., 2008, 2009).
Since increased C4BPA expression and C4BPA mutations were both associated with increased apoptosis, we
decided to further investigate the effect that patient-specificC4BPAmutations had on C4BPA expression levels.
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Figure 2. Patient-Specific C4BPA-Mutants Harbor Increased Intracellular C4BPA Expression and Apoptotic
Signaling in Response to Oxaliplatin
(A) Schematic representation of C4BPA mutations identified by TCGA in the COADREAD data set as well as the C4BPA
mutation found in RKO colorectal cancer cells (as reported in the Catalogue of Somatic Mutations in Cancer and shown in
red text) (cancer.sager.ac.uk). Each lollipop represents a missense mutation. Mutations in green text represent those
mutations tested further with the use of CRISPR knock-in cell lines. 182C > T, 563G > A and 1384G > A are highlighted
since they are the endogenous mutants experimentally tested in this study. Figure adapted from cbiorportal.org.
(B) HCT 116 C4BPAWT, HCT 116 C4BPA563G>A or HCT 116 C4BPA182C>T were treated with oxaliplatin (40 mM, 24 h).
Western blotting was carried out with the antibodies indicated. b-Actin was used as the loading control. n = 3.
(C) HCT 116 C4BPAWT, HCT 116 C4BPA563G>A or HCT 116 C4BPA182C>T were treated with oxaliplatin (40 mM, 24 h). The
graph represents the number of apoptotic/non-apoptotic cells expressed as a % of the whole population. Two different
clones are shown for each mutant (represented by different symbols). Individual dots represent values for each
independent experiment. Statistical significance was evaluated by two-way ANOVA, * = p < 0.05 between WT Oxa and
182C > T Oxa. n = 3.
(D) Colony survival assay carried out following treatment of HCT 116 C4BPAWT, HCT 116 C4BPA563G>A, or HCT 116
C4BPA182C>T with either vehicle of oxaliplatin (80 mM, 1 h). Individual dots represent values for each independent
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To this end, we transfected C4BPA-mutant expression vectors into HCT 116 cells (with previously depleted
endogenous C4BPA). When assessing C4BPA intracellular expression in this system, we noted that C4BPA
was localized predominantly in the cytoplasm in C4BPA WT cells (as also shown in Figures 1D and S1A) and
that C4BPAmutations did not alter this localization (Figure 1I). Importantly, as was observed in our initial exper-
iments usingC4BPAWT (HCT 116) andC4BPA-mutant (RKO) cells (Figure 1C), intracellular C4BPA expression in
response to oxaliplatin treatment was only increased in cells harboring C4BPA mutations (Figure 1I).
Patient-Specific C4BPA Mutants Harbor Increased Intracellular C4BPA Expression and
Apoptotic Signaling in Response to Oxaliplatin
In order to gain deeper insight into whether increased intracellular C4BPA could regulate the observed changes
in apoptosis, wedecided togenerateCRISPR knock-in (KI)mutant cell lines harboringdifferentC4BPAmutations
found in tumors from patients with colorectal cancer (Figures 2A and S2A). Generation of these cell lines, we
reasoned, would allow us to test, in an endogenous setting: 1) the effects of C4BPA mutations on changes in
C4BPA protein expression; and 2) whether increases in intracellular C4BPA levels affect apoptotic signaling.
We generated a cell line harboring the 182C > T mutation (cells referred to as HCT 116 C4BPA182C>T) since
we previously observed amarked induction of C4BPA protein levels following oxaliplatin treatment in cells over-
expressing this mutant (Figure 1I). We also generated a cell line harboring the 563G > Amutation (cells referred
to asHCT116C4BPA563G>A) since cells overexpressing thismutant showedhighbaselineC4BPAexpression and
minimal further increased C4BPA protein expression following oxaliplatin treatment (Figure 1I). HCT 116
C4BPA
182C>T cells, we reasoned, wouldprovide a representativemodel for increased expression of endogenous
intracellular C4BPA, while cell line HCT 116 C4BPA563G>A could serve as a direct control since this mutant does
not associatewith increased intracellular C4BPAexpression uponoxaliplatin treatment. In support of data shown
in Figure 1I, both CRISPR KI cell lines showed high levels of C4BPA following oxaliplatin treatment compared to
theWT cells, with the greatest increase inC4BPA expression observed inHCT 116C4BPA182C>T cells (Figure 2B).
As expected, HCT 116 C4BPA563G>A cells displayed high levels of C4BPA even under basal conditions, and ox-
aliplatin treatment caused only minimal further increase (Figure 2B).
Surprisingly, intracellular protein expression levels did not correlate with changes in mRNA levels in either
WT or mutant cell lines (Figure S2B). In addition, C4BPA mRNA expression levels in patients harboring
C4BPA mutations were not significantly different from that of patients without mutations (Figure S2C).
Together, these data suggest that transcriptional changes alone cannot explain the observed changes
in intracellular expression. Increased C4BPA protein expression in cell lysates from C4BPA-mutant cell
lines, however, correlated with a decrease in C4BPA secretion into conditioned media following oxaliplatin
treatment in two different C4BPA-mutant model systems (Figures S2D and S2E). These data suggest that
the observed increased intracellular expression could result from either decreased secretion in the cells
harboring sensitive C4BPA mutations or alternatively, an increased uptake of secreted protein. Interest-
ingly, no signs of increased ER stress marker BiP were observed in our mutants compared to C4BPA WT
cells (even when treated with tunicamycin and oxaliplatin), suggesting that increased intracellular accumu-
lation of C4BPA does not lead to increased ER stress (Figure S2F).
Next, we used our CRISPR KI cells as tools to understand the effects of oxaliplatin-induced intracellular
C4BPA protein expression on apoptosis sensitivity in further detail. When these cell lines were tested
in vitro, HCT 116 C4BPA182C>T displayed elevated levels of apoptosis compared to WT control (HCT 116
Figure 2. Continued
experiment (with three technical replicates per experiment). Statistical significance was evaluated by two-way
ANOVA, * = p < 0.05 between WT Oxa and 182C > T Oxa. n = 3.
(E) HCT 116 C4BPAWT, HCT 116 C4BPA563G>A, or HCT 116 C4BPA182C>T cells were injected subcutaneously into athymic
nude female mice. Growing tumors were treated with oxaliplatin (10 mg/kg) once tumors reached an average size of 60–
90 mm3 (labeled day 0). Treatment was repeated on day 3. Red arrows indicate day of oxaliplatin treatment. n = 7–9 mice
per group. Statistical significance was evaluated by two-way ANOVA, * = p < 0.05. Error bars represent the standard error
of the mean.
(F) Apoptosis was assessed by Terminal deoxynucleotidyl transferase dUTP Nick-End Labeling (TUNEL) staining in
sections from HCT 116 C4BPAWT, HCT 116 C4BPA563G>A, or HCT 116 C4BPA182C>T xenografts treated with oxaliplatin as
in (E). Graph represents the number of TUNEL-positive cells per field of view in 2–4 tumors per xenograft model. Statistical
significance was evaluated by two-way ANOVA, **** = p < 0.0001 between WT and 182C > T.
(G) Table describing the rationale behind the selection of C4BPAmutants generated by CRISPR/Cas9 technology and the
summary of C4BPA expression changes (D) and apoptosis level observed upon oxaliplatin treatment.
See also Figure S2.
ll
OPEN ACCESS



































































































































Figure 3. Patient-Specific C4BPA Mutants Display Decreased NF-kB Signaling
(A) HCT 116 C4BPAWT, HCT 116 C4BPA563G>A, or HCT 116 C4BPA182C>T were treated with oxaliplatin (40 mM, 24 h) or
vehicle. Treatment of HCT 116 C4BPAWT with TNF-a was used as a positive control. Treatment of HCT 116 C4BPAWT with
IkB kinase inhibitor ACHP (25 mM) was used as a negative control. NF-kB reporter assay was carried out. NF-kB reporter
luciferase activity – background renilla is shown.
(B) Cellular fractionation to separate nuclear and cytoplasm fractions followed by western blotting was carried out in HCT
116 C4BPAWT, HCT 116 C4BPA563G>A, or HCT 116 C4BPA182C>T cells treated with oxaliplatin (40 mM, 24 h). a-Tubulin was
used as a control for the cytoplasmic fraction, and LaminA/C was used as the nuclear control. n = 3. Nuclear fraction is
shown in the first lane as control.
(C and D) HCT 116 C4BPAWT, HCT 116 C4BPA563G>A, or HCT 116 C4BPA182C>T cells were transfected with either WT
C4BPA ormutantC4BPA (563G >A or 182C > T, respectively). Pull-down with RelA antibody was performed, and the input
and IP for those experiments is shown. Input was collected from the same experiment as IP. Western blotting was carried
out with the antibodies indicated. n = 2. IgG control is shown in the left lane of the blot.
(E) Quantification of IkBa/RelA relative abundance as shown in the western blot in (D).
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cells with no C4BPA mutation) or HCT 116 C4BPA563G>A cells (Figure 2C). HCT 116 C4BPA182C>T cells also
displayed the greatest decreased viability in response to oxaliplatin in clonogenic assays (Figures 2D and
S2G). These data are in line with our hypothesis that increased C4BPA intracellular expression following
oxaliplatin treatment contributes to increased apoptosis and oxaliplatin sensitivity. Furthermore, xeno-
grafts fromHCT 116 C4BPA182C>T cells displayed a significant tumor growth delay and increased apoptosis
following treatment with oxaliplatin compared to WT control or HCT 116 C4BPA563G>A (Figure 2E, 2F, and
S2H). These data support the importance of intracellular C4BPA expression and its correlation with
apoptosis sensitivity and improved oxaliplatin tumor response in specific C4BPA-mutant backgrounds. A
table describing the rationale behind the selection of C4BPAmutants generated by CRISPR/Cas9 technol-
ogy and the summary of C4BPA expression and apoptosis level changes observed upon oxaliplatin treat-
ment is shown in Figure 2G.
Patient-Specific C4BPA Mutants Display Decreased NF-kB Signaling
Since NF-kB activation can reduce chemosensitivity by promoting an anti-apoptotic transcriptional
response, we hypothesized that an interaction between C4BPA and RelA could regulate oxaliplatin-
induced apoptosis by altering NF-kB anti-apoptotic signaling (Barkett and Gilmore, 1999). In support of
this hypothesis, cells with the greatest levels of oxaliplatin-induced apoptosis and intracellular C4BPA
expression (HCT 116C4BPA182C>T) displayed reducedNF-kB reporter activity. Remarkably, NF-kB reporter
activity in this mutant cell line was reduced to levels comparable to those of WT cells treated with an IkB
kinase pharmacological inhibitor (ACHP) (used as a negative control). NF-kB inducer, TNFa, was used as
positive control in these experiments (Figure 3A). Decreased NF-kB activity could be a result of aberrant
expression or stabilization of NF-kB inhibitor, IkB, upon oxaliplatin treatment. Indeed, while C4BPA WT
cells showed a strong reduction in cytoplasmic IkBa levels upon oxaliplatin treatment, this reduction
was attenuated in the mutants. HCT 116 C4BPA182C>T cells that show the greatest apoptosis sensitivity,
largest increase in C4BPA expression, and least NF-kB activity showed no decrease in IkBa levels upon
treatment (Figure 3B).
These data suggest that in certain C4BPA-mutant backgrounds (such as the C4BPA182C>T alteration), the
activity of DNA-binding NF-kB proteins (such as RelA) is impaired, likely due to the increased expression
of the inhibitory NF-kB protein IkBa. Importantly, we observed increased binding of IkBa to RelA following
oxaliplatin treatment in C4BPA mutants, with the most significant increase in IkBa-RelA complex stability
observed, as expected, in HCT 116 C4BPA182C>T cells (Figures 3C–3F).
Increased IkBa Expression in C4BPA-Mutant Cell Lines Is Associated with Increased
Translation Markers
IkBa undergoes proteasomal degradation following phosphorylation by IKK kinases (Chen et al., 2000;
Karin and Lin, 2002). Thus, changes in IkBa stability inC4BPA-mutant cell lines could result from differences
in expression of IKK kinases or IkBa phosphorylation. However, we did not observe any decreased expres-
sion of the catalytic subunit of the IKK complex, IKKa in C4BPA-mutant cells, which also displayed robust
IkBa phosphorylation (Figures S3A and S3B). In addition, while significant increases in mRNA levels of IkBa
were observed in HCT 116 C4BPAWT and HCT 116 C4BPA563G>A cell lines, increased IkBamRNA levels did
not reach significance in HCT 116 C4BPA182C>T cells, indicating that transcriptional changes are also un-
likely to be the main contributors to the increased protein IkBa levels observed in these cells (Figures
S3C–S3E). Of note, since IkBa itself is thought to be an NF-kB target, the lack of significant increased
IkBa expression in HCT 116 C4BPA182C>T cells is in line with decreased NF-kB activity in this cell line as
shown in Figure 3A (Sun et al., 1993). Inhibition of protein synthesis has also been shown to activate NF-
kB activity by modulating the synthesis of IkB proteins (O’Dea et al., 2007). We assessed levels of protein
translation marker, phosphorylated 4E-BP1 (p4E-BP1), in C4BPA WT and C4BPA-mutant cell lines. Cells
harboring C4BPA-mutants (as well as WT overexpression) displayed increased levels of translation marker
p4E-BP1, particularly under unstimulated conditions (Figures S3F–S3H). Once again, this phenotype
Figure 3. Continued
(F) Proposed Model: Cells harboring ’sensitive’ C4BPA mutations (eg C4BPA182C>T) have increased oxaliplatin-induced
expression of intracellular C4BPA and cytoplasmic expression of IkBa which are associated with increased retention of
IkBa-NF-kB inhibitory complexes and a subsequent attenuated NF-kB signaling. These effects correlate with oxaliplatin-
induced apoptosis sensitivity and in vivo oxaliplatin tumor response as shown in Figure 2.
See also Figure S3.
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Figure 4. Altered NF-kB Signaling Regulates Apoptosis in Patient-Specific C4BPA-Mutant Backgrounds
(A) HCT 116C4BPAWT, HCT 116C4BPA563G>A, or HCT 116C4BPA182C>T cells were treated with either DMSO or IkB kinase
inhibitor ACHP (25 mM) and oxaliplatin (40 mM, 24 h). The graph represents the number of apoptotic/non-apoptotic cells
expressed as a % of the whole population. Individual dots represent mean values for each independent experiment, n =
3–4. Statistical significance was evaluated by two-way ANOVA, **** = p < 0.0001. * = p < 0.05.
(B) HCT 116 C4BPAWT cells were treated with either DMSO or ACHP (25 mM) and oxaliplatin (40 mM, 24 h). Western
blotting was carried out with the antibodies indicated. b-Actin was used as the loading control. n = 3. ACHP results in
stabilization of IkBa as expected.
(C) HCT 116 C4BPAWT, HCT 116 C4BPA563G>A, or HCT 116 C4BPA182C>T cells were transfected with either scramble (Scr)
or IkBa siRNA and treated with oxaliplatin (40 mM, 24 h). The graph represents the number of apoptotic/non-apoptotic
cells expressed as a % of the whole population. Individual dots represent mean values for each independent experiment.
Statistical significance was evaluated by two-way ANOVA, * = p < 0.05, ** = p < 0.01, *** = p < 0.001. n = 3.
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appeared particularly marked in cells harboring the most sensitive mutant, C4BPA182C>T. In order to inter-
rogate whether altered protein synthesis was contributing to increased IkBa protein levels, we used trans-
lation inhibitor cycloheximide (CHX). CHX blockade experiments suggest that IkBa levels can be regulated
at the translational level in C4BPA-mutant cell lines with CHX treatment reducing IkBa protein expression
back to WT levels (Figure S3I).
AlteredNF-kB Signaling Regulates Apoptosis in Patient-SpecificC4BPA-Mutant Backgrounds
Our data suggest that increased IkBa levels regulate NF-kB signaling inC4BPAmutants through regulation
of IkBa-RelA cytoplasmic retention. In order to test whether cytoplasmic retention of NF-kB inhibitory com-
plexes was mediating the increased apoptosis, we used IkB kinase inhibitor, ACHP, which prevents nuclear
translocation of NF-kB complexes due to increased IkBa stability (Figures 4A and 4B). We hypothesized
that treatment with ACHP should lead to the most pronounced increase in apoptosis levels in WT cells
and that no further increase in apoptosis levels would be observed in the most sensitive C4BPA mutants
(C4BPA182C>T) owing to the fact that nuclear translocation of NF-kB complexes is likely already impaired
in these cells. In support of our hypothesis, treatment with this inhibitor showed that stabilization of
IkBa complexes only caused a notable increase of apoptosis in the WT background. These data support
our hypothesis that, in C4BPA-mutant backgrounds, the activity of DNA-binding NF-kB proteins is
impaired by the increased expression of inhibitory proteins, likely retaining transcriptionally active RelA
in inhibitory complexes. As expected, further inhibition of nuclear translocation by ACHP had therefore
no additional effect on apoptosis induction in these mutants. To formally test the role of IkBa in apoptotic
signaling, we depleted IkBa and assessed apoptosis levels in C4BPA WT or C4BPA-mutant cell lines. We
reasoned that depletion of IkBa would relieve some of the inhibition on NF-kB signaling and ‘rescue’
apoptosis levels in C4BPA182C>T-mutant cells to levels comparable to C4BPAWT cells. As expected, reduc-
tion of IkBa levels (to protein levels comparable to those found in C4BPAWT) resulted in decreased
apoptosis in C4BPA182C>T-mutant cells to levels comparable to C4BPAWT cells treated with Scr siRNA (Fig-
ures 4C and 4D). These data suggest that under conditions of increased C4BPA intracellular expression, the
activity of DNA-binding NF-kB proteins is particularly impaired due to the increased expression of inhib-
itory NF-kB proteins.
Finally, to assess the role of NF-kB-DNA-binding family members in regulating apoptosis in C4BPA mu-
tants, we evaluated apoptosis following depletion of the DNA-binding NF-kB family members originally
identified as C4BPA predicted functional partners by STRING (Figure 1A). In these experiments, we again
used our CRISPR KI cells lines as tools to understand the effects of NF-kB family member depletion in cells
displaying varying levels of oxaliplatin-induced intracellular C4BPA protein expression. We hypothesized
that in those cells with the greatest increases in oxaliplatin-induced C4BPA levels, apoptotic sensitivity
and attenuated NF-kB anti-apoptotic responses (such as HCT 116 C4BPA182C>T) depletion of RelA/NF-
Figure 4. Continued
(D) HCT 116 C4BPAWT, HCT 116 C4BPA563G>A, or HCT 116 C4BPA182C>T cells were transfected with either scramble (Scr)
or IkBa siRNA and treated with oxaliplatin (40 mM, 24 h). Western blotting was carried out with the antibodies indicated.
b-Actin was used as the loading control. n = 3.
(E) HCT 116 C4BPAWT, HCT 116 C4BPA563G>A, or HCT 116 C4BPA182C>T cells were transfected with either Scr or RelA
siRNA and treated with oxaliplatin (40 mM, 24 h). The graph represents the number of apoptotic/non-apoptotic cells
expressed as a % of the whole population. Individual dots represent mean values for each independent experiment.
Statistical significance was evaluated by two-way ANOVA, * = p < 0.05. n = 3.
(F) HCT 116 C4BPAWT, HCT 116 C4BPA563G>A, or HCT 116 C4BPA182C>T cells were transfected with either Scr or RelA
siRNA and treated with oxaliplatin (40 mM, 24 h). Western blotting was carried out with the antibodies indicated. b-Actin
was used as the loading control. n = 3.
(G) HCT 116 C4BPAWT, or HCT 116 C4BPA182C>T cells were transfected with either Scr or NF-kB1 siRNA and treated with
oxaliplatin (40 mM, 24 h). Individual dots represent mean values for each independent experiment. n = 3. Statistical
significance was evaluated by two-way ANOVA, **p < 0.01.
(H) Proposed Model: Increasing stabilization of intracellular C4BPA correlates with increased cytoplasmic IkBa and
increased retention of RelA-IkBa in inhibitory complexes. These responses are particularly prominent in C4BPA-mutant
cell lines most sensitive to oxaliplatin-induced apoptosis (eg C4BPA182C>T). In contrast, when C4BPA levels are low (such
as in a WT setting), decreased cytoplasmic IkBa results in reduced retention of NF-kB in inhibitory complexes following
oxaliplatin treatment and reduced apoptosis levels. A mutant with no C4BPA stabilization (C4BPA563G>A) following
oxaliplatin treatment shows an intermediate apoptotic response correlating with intermediate levels of RelA-IkBa
retained in inhibitory complexes.
See also Figure S4.
ll
OPEN ACCESS
10 iScience 23, 101594, October 23, 2020
iScience
Article
kB1 would result in minimal additional changes to apoptosis levels. In support of our hypothesis, no
changes in apoptosis were observed following RelA depletion in C4BPA-mutant cell line HCT 116
C4BPA
182C>T (Figures 4E and 4F). These results were supported by experiments using NF-kB1 siRNA (Fig-
ures 4G and S4A). In contrast, as expected, RelA/NF-kB1 depletion experiments showed amarked increase
in apoptosis following oxaliplatin treatment in HCT 116 C4BPAWT cells (Figures 3A and 3B). HCT 116
C4BPA
563G>A cells were used as a control in RelA depletion experiments. As had been previously observed,
apoptosis in these cells never reached the high levels observed in HCT 116 C4BPA182C>T cells and instead
remained at an intermediate level between HCT 116 C4BPAWT and C4BPA182C>T cells (Figure 4E). These
data are in line with the lack of oxaliplatin-induced C4BPA expression in these cells. These data further sup-
port our hypothesis that cells with increased C4BPA protein expression following oxaliplatin treatment
display increased apoptosis due to impaired or inhibited NF-kB signaling.
Together these results highlight the importance of studying mutations in innate immunity-associated
genes as a tool to uncover novel functions. Using this approach, we identify that C4BPA has cancer-asso-
ciated functions that are distinct from its canonical role in the complement system. Specifically, we reveal
that C4BPA functions as a ‘rheostat,’ regulating oxaliplatin-induced apoptosis through modulation of NF-
kB signaling (Figure 4H).
DISCUSSION
Innate immunity-associated proteins with intracellular functions, such as TREX1, cGas, and STING, are
emerging as important contributors to treatment response and tumor progression (Cai et al., 2014; Van-
pouille-Box et al., 2017; Dunphy et al., 2018; Liu et al., 2018). However, despite the rising interest in tumor
cell-intrinsic functions for innate immunity-associated proteins, there is a lack of studies investigating the
intracellular roles of extracellular innate immunity-associated proteins and what regulates their intracellular
expression.
Here, we show that C4BPA is expressed intracellularly in a stress-responsive and mutation-dependent
manner. Using the study of specific C4BPA mutations found in patients, we uncover an unexpected, likely
immune-independent function for C4BPA. Experimentally, in vitro and/or in vivo, we show that intracellular
C4BPA expression in different C4BPA-mutant backgrounds appears to function as a ‘rheostat,’ tipping the
balance toward increased apoptosis following oxaliplatin treatment. In these experiments, cells harboring
C4BPA mutation (563G > A), with minimal increased stress-responsive C4BPA intracellular expression, as
expected, displayed a weaker apoptotic response and tumor regression in vivo than a sensitive mutation
(182C > T) displaying increased stress-responsive C4BPA intracellular expression. These data are in line
with increased C4BPA intracellular expression tipping the balance toward increased apoptosis. It is impor-
tant to note, however, that while cells harboring C4BPA mutation (563G > A) displayed a lower apoptotic
response than those harboring sensitiveC4BPAmutation (182C > T), these cells still showed a trend toward
increased apoptosis in comparison to WT cells. These data probably reflect the fact that C4BPA levels
following oxaliplatin treatment in these cells remained higher than those of WT cells.
Mechanistically, we show that the increased apoptosis observed in oxaliplatin-sensitive C4BPA mutants is
associated with attenuated NF-kB-dependent anti-apoptotic responses. We propose that in cells with
increased stress-responsive C4BPA intracellular expression, transcriptionally active NF-kB proteins are
impaired due to the elevated expression levels of NF-kB inhibitory proteins. Indeed, following oxaliplatin
treatment, we observed increased expression of cytoplasmic inhibitory NF-kB protein, IkBa, in sensitive
C4BPA-mutant cells as well as increased IkBa-RelA complexes. These cells also displayed decreased
NF-kB reporter activity. We propose that increased C4BPA protein levels following oxaliplatin treatment
could contribute to increased stability of IkBa-RelA complexes.
Links between NF-kB activation and complement, specifically C3, have been recently suggested in the
context of Alzheimer’s disease and viral and bacterial infections (Lian et al., 2014; Tam et al., 2014). How-
ever, no associations between these two pathways and how theymay cooperate to regulate apoptosis have
been suggested in a cancer context, which likely reflects the fact that intracellular roles for complement
proteins have only recently been considered (Liszewski et al., 2013; Arbore et al., 2017; Elvington et al.,
2017; Kremlitzka et al., 2019). Of note, a recent study reported that complement factor properdin may
act as a tumor suppressor in breast cancer models by upregulating ER-activated pro-apoptotic transcrip-
tion factorDDIT3 (Block et al., 2019). Furthermore, Complement C1q-Binding Protein (C1QBP) was recently
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shown to play an important role in the DNA damage response by binding, stabilizing, and controlling
MRE11’s nuclease activity (Bai et al., 2019). These studies, like ours, highlight the importance of investi-
gating intracellular functions of complement proteins.
Interestingly, C4BP can bind DNA mainly through a patch of positively charged amino acids on C4BPA
(Trouw et al., 2005). We did not investigate the DNA binding capabilities of C4BPA in our models. How-
ever, given that intracellular C4BPA is primarily localized in the cytoplasmic/extranuclear space, it would
be interesting to investigate whether C4BPA can bind cytosolic nucleic acids in future studies. Since the
environment of the cytoplasm is distinct from that of the extracellular space, it is possible that the struc-
tural features of intracellular C4BPA might be different from those of C4BPA present extracellularly (Ló-
pez-Mirabal and Winther, 2008). Interestingly, Hofmeyer et al. reported that the C4BPA heptamer is very
stable due to a large number of hydrophobic interactions and formation of electrostatic, disulfide, and
hydrogen bonds (Hofmeyer et al., 2013). Whether intracellular C4BPA is present as a single chain or mul-
timer was not investigated in this study. However, it is possible that, even if disulfide bonds are not
formed efficiently intracellularly, C4BPA might still be present in a multimeric form as occurs in the
main C4BP isoform.
Overall our study provides the first description of stress-specific and mutation-dependent intracellular in-
duction of C4BPA expression in cancer cells and describes the importance of the interplay between C4BPA
and NF-kB in regulating oxaliplatin-induced apoptosis sensitivity in colorectal cancer.
Limitations of the Study
Here we uncover that, in colorectal cancer cells, C4BPA has an intracellular role in the regulation of
apoptosis following oxaliplatin treatment. Future studies should test a wider range of DNA-damaging
agents and cell types. Similarly, testing the effect of C4BPA mutations on tumor progression and treat-
ment response in other tumor models would be interesting, given that C4BPA mutations are associ-
ated with improved survival in all epithelial cancer types queried. By studying patient-specific C4BPA
mutations, we have focused on the description of an unexpected non-canonical function for C4BPA
but have not investigated whether these mutations can impact canonical complement regulation.
Furthermore, whether intracellular C4BPA interacts with its canonical ligand/binding partners intracel-
lularly remains to be formally tested. Of note, expression of C4 and C4BPB in the colorectal cancer
cell lines used in this study is very low ([Roumenina et al., 2019] and https://www.ebi.ac.uk). We cannot
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Figure S1: Intracellular C4BPA interacts with RelA, related to Figure 1. (A) 
HCT 116 C4BPAWT were transfected with WT C4BPA and stained for C4BPA 
and Tubulin (top) or C4BPA and BiP (bottom). Representative images are 
shown. Scale bar (shown as white bar) = 10 µm. DAPI = blue. Differences in 
C4BPA staining reflect different levels of C4BPA following overexpression in 
different experiments. (B) Colony survival assay of RKO (colorectal cancer cells 
with endogenous C4BPA mutation) and HCT 116 (colorectal cancer cells without 
C4BPA mutation) treated with either DMSO, or oxaliplatin (40 µM, 1 hour) either 
alone or in combination with 5-FU (0.1 µg/ml, 1 hour). Individual dots represent 
values for each independent experiment (with three technical replicates per 
experiment), n = 3. Statistical significance was evaluated by two-way ANOVA, * = 
p < 0.05. (C) RKO (colorectal cancer cells with endogenous C4BPA mutation) 
and HCT 116 (colorectal cancer cells without C4BPA mutation) were treated with 
oxaliplatin 40 µM, 24 hours). Western blotting was carried out with the antibodies 
indicated. β-Actin was used as the loading control. n=3. (D) The graph 
represents the number of apoptotic/non-apoptotic cells expressed as a % of the 
whole population. HCT 116 and RKO cells treated with oxaliplatin (40 µM, 24 
hours). Individual dots represent values for single fields of view in each individual 
independent experiment. n = 3. Statistical significance was evaluated by 
evaluated by two-way ANOVA, * = p < 0.05. A representative image of a normal 
(top) and apoptotic cell (bottom) is also shown to the left of the graph. (E) The 
graph represents the number of apoptotic/non-apoptotic cells expressed as a % 
of the whole population. HCT 116 cells were transfected with WT C4BPA 
(labeled WT OE) or empty vector (pcDNA 3.1). Cells were treated with oxaliplatin 
(40 µM, 24 hours). Individual dots represent values for single fields of view in 
each individual independent experiment. n = 3. Statistical significance was 
evaluated by two-way ANOVA, **** = p < 0.0001. (F) Graph showing the 
alteration frequency of mutations, amplifications, deep deletions or multiple 
alterations across cancer types. Data downloaded from cbioportal.org. (G) KM 
curve for overall survival of COADREAD patients with mutations in C4BPA vs 
patients without mutation (p=0.07001). (H) KM curve showing survival probability 
when COADREAD patients with C4BPA mutations are grouped according to age 
(product-limit survival estimates with number of subjects at risk). (I) C4BPA 
mRNA expression in tumor (T) and normal tissue (N) of patients with colon 
(COAD) or rectal (READ) cancer is shown. Log scale used = Log2(TPM+1). Each 
dot represents sample expression. Differential gene expression assessed by 
ANOVA. ILog2FCI Cutoff = 1, q-value=0.01. (J) Immune infiltration signature 
associated with cytolytic activity was assessed in patients with and without 
C4BPA mutations in COADREAD patients. (K) Immune infiltration signature 
associated with cytotoxic lymphocytes was assessed in patients with and without 
C4BPA mutations in COADREAD patients. In boxplots, the box is drawn from the 
25th (Q1) to the 75th (Q3) percentile. The horizontal line represents the 50th 
percentile or median. Whiskers extend to the maximum or minimum data values. 
If there are outliers (values extending beyond 1.5 x IQR), the whiskers extend to 




Figure S2: Patient-specific C4BPA mutants harbor increased intracellular 
C4BPA expression and apoptotic signaling in response to oxaliplatin, 
related to Figure 2. (A) HCT 116 cells with one of two specific C4BPA point 
mutations (563G>A or 182C>T, denoted HCT 116 C4BPA563G>A or HCT 116 
C4BPA182C>T respectively) were generated by CRISPR/Cas9 technology. HCT 
116 C4BPAWT denotes HCT 116 cells that were targeted with a control vector so 
that no C4BPA mutation was introduced. Sequencing chromatograms are shown 
confirming the point mutations. Red chromatogram = HCT 116 C4BPAWT, green 
chromatogram = HCT 116 C4BPA563G>A and blue chromatogram = HCT 116 
C4BPA182C>T. (B) mRNA expression of C4BPA/18S is shown. qPCR was carried 
out following treatment of HCT 116 C4BPAWT, HCT 116 C4BPA563G>A or HCT 
116 C4BPA182C>T with oxaliplatin (40 µM, 24 h), n=3. Individual dot represent 
average mRNA expression from each of 3 independent experiments. Data with 2 
different C4BPA primers is shown. (C) C4BPA mRNA expression in patients with 
or without C4BPA mutations is shown. Data downloaded from cbioportal.org. In 
boxplots, the box is drawn from the 25th (Q1) to the 75th (Q3) percentile. The 
horizontal line represents the median. Whiskers extend to the maximum or 
minimum data values. If there are outliers (values extending beyond 1.5 x IQR), 
the whiskers extend to 1.5 x the IQR. IQR = Q3-Q1. (D) RKO and HCT 116 were 
treated with oxaliplatin (40 µM, 24 h) and conditioned media was collected. 
Western blotting was carried out with the antibodies indicated. Ponceau Staining 
(PS) was used as the loading control. n=3. (E) HCT 116 cells where C4BPA had 
been depleted by CRISPR/Cas9 technology were transfected with C4BPA 
mutant constructs, each representing a mutation found in cancer patients from 
the TCGA data set. Wild type (WT) C4BPA and empty pcDNA3.1 constructs 
were also transfected as controls. Cells were treated with oxaliplatin (40 µM, 24 
hours) and conditioned media was collected. Western blotting was carried out 
with the antibodies indicated. Non-specific (NS) band was used as the loading 
control. n=3. (F) HCT 116 C4BPAWT, HCT 116 C4BPA563G>A or HCT 116 
C4BPA182C>T were treated with oxaliplatin (40 µM, 24 h). Western blotting was 
carried out with the antibodies indicated. α-Tubulin was used as the loading 
control. n=3. (G) Colony survival assay carried out following treatment of HCT 
116 C4BPAWT, HCT 116 C4BPA563G>A or HCT 116 C4BPA182C>T cells with 
different oxaliplatin doses (for 1 h). Individual dots represent technical replicates 
for an individual experiment. Error bars indicate standard deviation. (H) TUNEL 
staining was performed in tumors grown from HCT 116 C4BPAWT, HCT 116 
C4BPA563G>A or HCT 116 C4BPA182C>T cells and treated with oxaliplatin as in 
(2E). Representative images for HCT 116 C4BPAWT, HCT 116 C4BPA563G>A or 













































































































































































































































Figure S3: Increased IκBα expression in C4BPA mutant cell lines is 
associated with increased translation markers, related to Figure 3. (A) HCT 
116 C4BPAWT, HCT 116 C4BPA563G>A or HCT 116 C4BPA182C>T were treated 
with oxaliplatin (40 µM, 24 h) Western blotting was carried out with the antibodies 
indicated. α-Tubulin was used as the loading control. PS = ponceau staining n=2. 
(B) HCT 116 C4BPAWT, HCT 116 C4BPA563G>A or HCT 116 C4BPA182C>T were 
treated with oxaliplatin (Oxa, 40 µM, 24 h) Western blotting was carried out with 
the antibodies indicated. β-Actin was used as the loading control. n=2. (C) mRNA 
expression of IκBα/18S is shown. qPCR was carried out following treatment of 
HCT 116 C4BPAWT cells with oxaliplatin (40 µM, 24 h), n=4. Individual dot 
represent average mRNA expression from each of 4 independent experiments. 
(D) mRNA expression of IκBα/18S is shown. qPCR was carried out following 
treatment of HCT 116 C4BPA563G>A cells with oxaliplatin (40 µM, 24 h), n=4. 
Individual dot represent average mRNA expression from each of 4 independent 
experiments. (E) mRNA expression of IκBα/18S is shown. qPCR was carried out 
following treatment of HCT 116 C4BPA182C>T cells with oxaliplatin (40 µM, 24 h), 
n=4. Individual dot represent average mRNA expression from each of 4 
independent experiments. (F) HCT 116 C4BPAWT or HCT 116 C4BPA563G>A were 
treated with oxaliplatin (Oxa, 40 µM, 24 h). Western blotting was carried out with 
the antibodies indicated. α-Tubulin was used as the loading control. n=2. (G) 
HCT 116 C4BPAWT or HCT 116 C4BPA182C>T were treated with oxaliplatin (Oxa, 
40 µM, 24 h). Western blotting was carried out with the antibodies indicated. α-
Tubulin was used as the loading control. n=2. (H) HEK293T cells were 
transfected with different C4BPA mutants (corresponding to C4BPA mutations 
found in COADREAD patients), or WT C4BPA. UNT = Untransfected. Western 
blotting was carried out with the antibodies indicated. β-Actin was used as the 
loading control. n=2. (I) HCT 116 C4BPAWT, HCT 116 C4BPA563G>A or HCT 116 
C4BPA182C>T were treated with cycloheximide (CHX, 10 mg/ml, 24 h). Western 
blotting was carried out with the antibodies indicated. α-Tubulin was used as the 










Figure S4: Altered NF-κB signaling regulates apoptosis in patient-specific 
C4BPA mutant backgrounds, related to Figure 4. HCT 116 C4BPAWT cells 
were transfected with either scramble (Scr) or NF-κB1 siRNA. Western blotting 












Table S1, relating to Figure 1. Table summarizing the C4BPA mutations 
found in colorectal cancer patients from TCGA data sets. Data downloaded 
from cbioportal.org. 
  









Table S2. Relating to Figure 1. Table summarizing data from Gene Ontology 
analysis of proteins differentially expressed in COADREAD patients with 
C4BPA mutations compared to patients without C4BPA mutations (From 




Term PValue Fold Enrichment Bonferroni Benjamini FDR
GO:0042981 3.73E-08 8.07641791 2.87E-05 2.87E-05 5.70E-05
GO:0043067 4.13E-08 7.996847291 3.18E-05 1.59E-05 6.31E-05
GO:0010941 4.29E-08 7.967411043 3.31E-05 1.10E-05 6.56E-05
GO:0043066 1.87E-06 12.22870056 0.00143635 3.59E-04 0.00285101
GO:0043069~n2.05E-06 12.0583844 0.00157689 3.16E-04 0.00313018
GO:0060548~n2.09E-06 12.02488889 0.00160634 2.68E-04 0.00318868
GO:0010033~re2.09E-06 7.505131761 0.00161054 2.30E-04 0.00319703
GO:0009725~re2.37E-06 11.79553134 0.00182566 2.28E-04 0.00362443
GO:0007242~i 3.38E-06 5.169936306 0.0026007 2.89E-04 0.00516507
GO:0042127~re4.32E-06 6.875730623 0.0033182 3.32E-04 0.00659237
GO:0009719~re4.56E-06 10.68879012 0.00350299 3.19E-04 0.00696014
GO:0042325~re1.14E-05 9.289613734 0.00877051 7.34E-04 0.01747151
GO:0019220~re1.48E-05 8.925690722 0.0113615 8.79E-04 0.02266197
GO:0051174~re1.48E-05 8.925690722 0.0113615 8.79E-04 0.02266197
GO:0006916~a2.62E-05 15.7607767 0.01996373 0.00143937 0.03999064
GO:0042493~re3.29E-05 15.03111111 0.02499962 0.0016864 0.05020449
GO:0009968~n3.67E-05 14.69104072 0.02785446 0.00176405 0.05601767
GO:0014070~re5.63E-05 22.36033058 0.04245696 0.00254878 0.08601634
GO:0010648~n6.36E-05 13.0916129 0.04776105 0.00271516 0.09702394
GO:0010604~p7.42E-05 5.682707118 0.05551888 0.00300178 0.11323251
GO:0001666~re8.39E-05 20.19104478 0.06253293 0.00322348 0.12799981
GO:0070482~re1.02E-04 19.18865248 0.07566942 0.00373992 0.15595092
GO:0044087~re1.05E-04 19.05352113 0.0776868 0.00366918 0.16027785
GO:0006468~p1.14E-04 6.490194903 0.08385787 0.00380075 0.17357153
Transparent Methods 
“Further information and requests for resources and reagents should be directed 
to and will be fulfilled by the Lead Contact, Monica Olcina 
(monica.olcinadelmolino@uzh.ch). 
 
KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Antibodies 




β-actin  Sigma-Aldrich Cat# A5441  
RRID:AB_476744 
γH2AX  Upstate Millipore Cat# 07-164 











RelA  Cell Signaling 
Technology 
Cat# 3034 and 8242 
RRID:AB_330561 and RRID:AB_10859369 
RelA  Bethyl Cat# A301-824A-M 
RRID: AB_2780149 
IκBα Novus Cat# NB100-56507, 
 RRID:AB_838388 










α-Tubulin  Fitzgerald Cat# I0R-T130A 
RRID:AB_1279269 










Phospho-IκBα (Ser32)  Cell Signaling 
Technology 
Cat# 2859 








GRP78/HSPA5/BiP  R&D Systems Cat # MAB4846 
RRID:AB_2233235 
Alexa-Fluor A459 anti-rabbit 
IgG 
Invitrogen Cat# A-21207 
RRID:AB_141637 
Alexa-Fluor A488 anti-mouse 
IgG 
Invitrogen Cat# A-21202 
RRID:AB_141637 
Alexa-Fluor A488 anti-rabbit 
IgG 
Invitrogen Cat# A-11008 
 RRID:AB_143165 
Alexa-Fluor A647 anti-mouse 
IgG 
Invitrogen Cat# A-21235 
RRID:AB_2535804 










Critical Commercial Assays 
ApopTag® Peroxidase In 
Situ 
Apoptosis Detection Kit 
Millipore Cat# 7100 
 
NF-κB assay BPS Biosciences Cat# 60614 
QuickChange® Site-directed 
mutagenesis kit  
Agilent Cat# 200521 
Fractionation Kit Cell Signaling 
Technology 
Cat #9038 
Raw and analyzed data  This paper Supplemental Tables 
Experimental Models: Cell Lines 
HCT 116 ATCC® Cat# CCL-247TM 
RRID:CVCL_0291 
RKO ATCC® Cat# CRL-2577 
RRID:CVCL_0504 
HEK293T ATCC® Cat# CRL-3216 
RRID:CVCL_0063 
HCT 116 C4BPAWT  
HCT 116 C4BPA182C>T  
HCT 116 C4BPA 563G>A 






TARGETplus RelA siRNA 
Dharmacon L-003533 
SMARTpool: ON-
TARGETplus NFKBIA siRNA 
Dharmacon J-004765 















Software and Algorithms 
DESeq2 (Love et al., 
2014) 
RRID: SCR_015687 
GSEA   RRID:SCR_003199 
RPPA   RRID: SCR_016649 
 
















Cell lines and treatments. RKO and  HCT 116  (human colorectal cancer), 
cells originally purchased from ATCC® were a kind gift Ester Hammond (Oxford, 
UK). HEK293T cells were purchased from ATCC®. Cells were grown in DMEM 
with 10% FBS, in a standard humidified incubator at 37oC and 5% CO2.  All cell 
lines were routinely mycoplasma tested and found to be negative. Oxaliplatin 
(Oxa) was used at a range of concentrations for either 1 or 24 hours as stated in 
figure legends. 5-fluorouracil (5-FU) was used at a concentration of 0.1 µg/ml 
for either 1 or 24 hours as stated in the figure legends. ACHP (Tocris) was used 
at a concentration of 25 µM as previously described (Sanda et al., 2005). 
Cycloheximide (CHX) (Sigma-Aldrich) was used at a concentration of 10 µg/ml. 
Tunicamycin (Sigma-Aldrich) was used at a concentration of 1 µg/ml. 
 
CRISPR/Cas9 mediated depletion of C4BPA was performed as previously 
described (Ran et al., 2013). sgRNA sequence 
(CACCGACAAACGATGCAGACACCC) was cloned into PMX459 vector 
containing Cas9. This plasmid was transfected into HCT 116. Clones were 
isolated following puromycin selection. 
 
CRISPR/Cas9 mediated generation of stable C4BPA point mutation cell lines 
was carried out using the CRISPR/Cas9 based EGE system (Biocytogen). In 
brief, sgRNA and targeting vector were electroporated into HCT 116 cells. 
sgRNAs were designed to target c.C182T, p61L (resulting cell line named HCT 
116 C4BPA182C>T) and cG563A, pG188D. (HCT 116 C4BPA563G>A). sgRNAs were 
designed for high activity and low off-target effects. Two separate clones for each 
mutation were tested in functional assays. Colonies were picked following 
puromycin selection and screened by PCR. Following clonal growth of cells in 
semisolid media, resistant clones were picked and expanded for further analysis 
including validation by sequencing (Figure S2). Clones that were transfected but 
where C4BPA was not mutated are designated HCT 116 C4BPA WT and were 
used as controls.  
 
DNA Transfections. C4BPA point mutants were generated with the use of the 
QuickChange® Site-directed mutagenesis kit (Agilent). Point mutations 
corresponding to coding missense mutations found in colorectal cancer TCGA 
patients were generated and transfected with the use of Lipofectamine 2000 
(Invitrogen) into HCT 116 where C4BPA had been depleted by CRISPR/Cas9. 
 
siRNA transfection. RelA, IκBα , NFκB1 siRNA pool (Dharmacon) or non-
targeting RNAi negative control (Dharmacon) were transfected into HCT 116WT, 
HCT 116563G>A or HCT 116182C>T cells using RNAi Max (Invitrogen) at a final 
concentration of 50 nM; according to the manufacturers’ instructions. Cells 
were harvested 72 hours post- transfection. 
 
NF-κB reporter assay. NF-κB reporter kit was used (BPS Biosciences #60614) 
according to manufacturer’s instructions. NF-κB luciferase reporter vector 
constitutively expressing a Renilla luciferase vector was transfected into HCT 
116 C4BPA WT, HCT 116 C4BPA 563G>A or HCT 116 C4BPA 182C>T cells with 
Lipofectamine 3000 (Invitrogen). Negative control reporter consisting of a non-
inducible luciferase vector also constitutively expressing a Renilla luciferase 
vector was also transfected. 48 hours post-transfection cells were treated with 40 
µM oxaliplatin (Sigma-Aldrich) or vehicle (H2O). 6 hours of TNFα treatment 
(Sigma-Aldrich) was used as positive control for NF-κB induction. ACHP (Tocris) 
was used at a concentration of 25 µM as a negative control for NF-κB activity. 
Luciferase activity was measured using the Dual-Reporter® Assay System 
(Promega). Luciferase reading was divided by the Renilla reading to calculate the 
NF-κB activity. Background reading corresponds to the reading of the wells 
transfected with negative control vector. NF-κB activity-background is shown. 
Three independent experiments were carried out. 
 
Immunoblotting. Sample preparation and immunoblotting was carried out as 
stated in Mendeley Data: https://data.mendeley.com/datasets/sks63zhwby/1. 
Briefly, cells were lysed in UTB (9 M urea, 75 mM Tris-HCl pH 7.5 and 0.15 M 
β-mercaptoethanol) and sonicated briefly. Antibodies used were: C4BPA 
(Thermo-Fisher Scientific), β-actin (Santa Cruz), γH2AX (Upstate), α-tubulin 
(Fitzgerald and Sigma-Aldrich), hFAB™ Rhodamine Anti-Tubulin (Bio-Rad), total 
IκBα (Cell Signaling Technology and Novus). RelA/p65 (Cell Signaling 
Technology and Bethyl) p105/p50 NFκB1, Lamin A/C, Bax, Cleaved Caspase 3, 
phospho-4E-BP1 Thr37/46, IKKα , Phospho-IκBα (Ser32)  (Cell Signaling 
Technology) and GRP78/HSPA5/BiP (R&D systems). The BioRad Chemidoc 
XRS system was used. In each case experiments were carried out in triplicate 
and a representative blot is shown unless otherwise stated.  
 
Immunoprecipitation. Immunoprecipitation was carried out as in (Li et al., 
2019). Whole cell extracts were incubated overnight with antibodies at 4oC while 
rotating. The following day, extracts were incubated for 3 hours at 4oC with 
protein G Dynabeads (Thermo Fisher Scientific) while rotating. Beads were 
washed three times with ice-cold wash buffer (50 mM Tris-HCl, pH 7.5, 150 mM 
NaCl, 1 mM EDTA, 0.05% NP-40) following incubation. Elution of proteins was 
carried out with IgG elution buffer (Thermo Fisher Scientific) at room temperature 
for 10 minutes on gentle vortex. The final elution was collected and neutralized 
using 1/10 volumes of 1 M Tris-HCl, pH 9.0. RelA immunoprecipitation was 
carried out with RelA antibody (Bethyl). Secondary antibody mouse-anti-rabbit 
and goat anti-mouse antibodies were used (as stated in the Key Resource 
Table). 
 
Subcellular fractionation. The Cell Signaling Technology fractionation kit (Cell 
Signaling Technology, cat# 9038) was used according to manufacturer’s 
instructions. Cells were harvested into 0.5 ml ice-cold PBS and counted using 
Trypan Blue and CountessTM II automated cell counter. For every 5 x 106 cells, 
100 µl of suspension was aliquoted as whole cell lysate (WCL). The remaining 
sample was centrifuged for 5 minutes at 500 x g at 4oC and the pellet was 
resuspended in 500 µl of “cytoplasminc isolation” buffer.  Following a 5 second 
vortex and 5 minute incubation on ice the sample was centrifuged for 5 minutes 
at 500 x g and the supernatant was saved as the cytoplasmic fraction. The 
remaining pellet was resuspended in 500 µl of “membrane and organelle 
isolation” buffer and vortexed for 15 seconds and incubated on ice for 5 minutes 
followed by centrifugation for 5 minutes at 8000 x g. The remaining supernatant 
was collected as the membrane/organelle fraction. The pellet was resuspended 
in 250 µl of “cytoskeleton/nucleus isolation” buffer and sonicated for 5 seconds 
on medium power using a Bioruptor® (Diagenode). Western blotting was then 
carried out as described above. An adapted version of the REAP fractionation 
method was also used (Suzuki et al., 2010). Cells were harvested in 1 ml ice-cold 
PBS followed by centrifugation at top speed for 10 seconds at 4oC. Pellets were 
resuspended in 900 µl of 0.1% NP-40 in PBS. 300 µl of this suspension was 
saved as WCL. The remaining sample was centrifuged at 13000 x g, 4 oC for 10 
seconds and 300 µl of supernatant was aliquoted as the cytoplasmic fraction. 
The remaining pellet was resuspended in 0.1% NP-40 in PBS and centrifuged at 
13000 x g, 4 oC for 10 seconds. The remaining pellet was resuspended in 100-
180 µl (depending on size) of 0.1% NP-40. Protein was quantified (using 
PierceTM BCA protein assay kit, ThermoFisher Scientific, cat #23225) and 
western blotting was carried out as stated above.  
 
Immunofluorescence. Staining was carried out as previously described and as 
stated in Mendeley Data: https://data.mendeley.com/datasets/sks63zhwby/1	  
using C4BPA antibody (Thermo-Fisher Scientific), hFABTM Rhodamine anti-
tubulin (BioRad) or BiP (Novus) (Olcina et al., 2013). Cells were visualized using 
a DSM6000, DMi8 or DMI6000 (Leica) microscope. In each case experiments 
were carried out at least in triplicate.  
 
Apoptosis assays. Apoptosis counts were performed as previously described 
by assessing morphology following DAPI staining (Olcina et al., 2015). Adherent 
and detached cells (in media) were collected and fixed in 4% PFA for 15 minutes 
at room temperature. PFA was removed and cells were washed in 1 ml PBS. 10 
µl of fixed cells in PBS was placed in each slide and mixed with ProLong® Gold 
mounting medium with DAPI (Invitrogen/Life technologies). A coverslip was 
placed on top of the sample and slides were left to dry overnight. Slides were 
imaged using a DSM6000, DMi8 or DMI6000 (Leica) microscope with 40x or 60x 
oil objectives.  The number of cells with fragmented DNA and the total number of 
cells per field was counted (with typically at least 10 fields counted for every 
treatment).  
 
TUNEL assay (Millipore) was used to stain 4 µm paraffin-embedded tumor 
sections. Stained slides were scanned with a NanoZoomer 2.0-RS Digital Slide 
Scanner (Hamamatsu). 15 randomly chosen fields of view (from at least 2 
different tumors per condition) at 10x magnification were selected for analysis via 
ImageJ software (NIH). Images were first converted to 8-bit black and white, then 
the threshold was adjusted to 0-200 to eliminate background signal. The 
remaining particles larger than 10 square pixels were counted. 	  
 
Clonogenic survival assay. Colonies (of at least 50 cells) were allowed to form 
for 10-14 days. Colonies were then stained with crystal violet and counted. 
Clonogenic survival was determined by dividing the number of counted colonies 
by the number of cells plated. 
 
Xenograft study. HCT 116 C4BPA WT, HCT 116 C4BPA 563G>A or HCT 116 
C4BPA 182C>T cells (1.5 x 106) were injected subcutaneously into 8-10 week old 
female Athymic nude mice (Charles Rivers) at a single dorsal site. Growing 
tumors (average, 60-90 mm3) were treated with oxaliplatin (10 mg/kg) at day 0 
and 3. Tumors were measured with the use of calipers and volumes calculated 
by the ellipsoid estimation method as previously described (Taniguchi et al., 
2014). All procedures were performed in accordance with the National Institutes 
of Health (NIH) guidelines for the use and care of live animals (approved by the 
Stanford University Institutional Animal Care and Use Committee). 
 
qPCR. RNA was extracted using Trizol (Invitrogen/Life Technologies). iScript 
cDNA synthesis kit was used to reverse transcribe cDNA from total RNA 
according to manufacturer’s instructions. Relative mRNA levels were calculated 
using the standard curve methodology. Primers used: 18S F: 
TAGAGGGACAAGTGGCGTTC, 18S R: CGGACATCTAAGGGCATCAC. C4BPA 
F1:	   TTCACACTGGTCAGCTCCAG,	   C4BPA R1: GGTTCTGTTCCCAGAGCAAG, 
C4BPA F2: GGTTCTGTTCCCAGAGCAAG, C4BPA R2: 
TGGGTACCAGGTTCTGTTCC, NFKBIAF: ACCTGGTGTCACTCCTGTTGA, 
NFKBIAR: CTGCTGCTGTATCCGGGTG 
 
TCGA RNA-sequencing (RNA-seq) analysis. TCGA raw counts were acquired 
from the TCGA data portal using TCGA-Assembler. Counts were rounded then 
inputted into DESeq2 to perform differential expression analysis using default 
size factor normalization (Love et al., 2014). The Independent filtering and Cooks 
Cutoff flags were set to FALSE. Benjamini–Hochberg method was used for 
multiple hypothesis testing. 
 
GSEA. Gene set enrichment analysis was performed on the output of DESeq2 
as defined earlier using COADREAD expression data where groups were defined 
by C4BPA mutational status. GSEA preranked was used with the signed log p-
value output of DESeq2 as the ranking metric.   
	  
Clinical association analysis. For the association of mutations to survival, 
somatic mutations were only evaluated if they occurred in at least 3 samples. 
Pan-cancer level survival analysis was performed using a multivariable cox 
regression on mutational status controlling for type, age and gender (coxph in R). 
Wald test p-values are reported. Individual cancers were evaluated with a 
univariate model on mutational status. 
 
RPPA data analysis. Significantly differentially expressed RPPA data was 
obtained using rowttests in the genefilter package from TCGA patients with 
C4BPA mutations compared to patients without mutations and was analyzed 
though DAVID Bioinformatics Resources (6.7) Functional annotation tool (using 
Ensemble gene ID) (accessed August 4 2016)1,12. Only expression changes with 
p<0.05 were included in the list. GOTERM_BP_FAT was used as the category. 
 
Immune infiltration analysis. Samples with and without C4BPA mutations were 
compared for enrichment of immune infiltration signatures using RNAseq data. 
Single sample GSEA (ssGSEA) was performed with immune signatures derived 
from MCP-counter (Becht et al., 2016a)(Becht et al., 2016b). ssGSEA scores 
were compared between mutant and non mutant groups using a student’s t-test 
to find significant differences in cytolytic activity and cytotoxic lymphocytes. 
 
Differential tumor vs normal tissue expression data analysis. C4BPA mRNA 
expression data for tumor and normal tissue of patients with colon (COAD) or 
rectal (READ) cancer was accessed and downloaded through GEPIA 
(http://gepia.cancer-pku.cn)(July 2nd 2020). Matched TCGA normal and GTEx 
data is shown. Differential gene expression assessed by ANOVA. ILog2FCI 
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